Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Acute Kidney Injury I: Introduction01:22

Acute Kidney Injury I: Introduction

Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modeling Fabry nephropathy: insights from experimental systems towards precision nephrology.

Disease models & mechanisms·2026
Same author

Evaluating Iterative Deep Learning as a Labeling-Efficient Strategy for Tubular Segmentation in Digital Nephropathology.

Journal of imaging informatics in medicine·2026
Same author

Exploring Sex-Specific High-Sensitivity Cardiac Troponin Thresholds for Rule-Out of Non-ST-Elevation Myocardial Infarction.

Clinical chemistry·2026
Same author

Complement Genomics and Steroid Pharmacogenomics Define Heterogeneity in Progression and Treatment of IgA Nephropathy.

Journal of the American Society of Nephrology : JASN·2026
Same author

What practicing pathologists and oncologists should know about the new computational pathology-based companion diagnostic tools.

The Journal of pathology·2026
Same author

StainStyleSampler: clustering-based sampling of whole slide image appearances.

Diagnostic pathology·2026

Related Experiment Video

Updated: May 10, 2026

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice
05:39

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice

Published on: July 8, 2020

Mortality in patients with IgA nephropathy.

Thomas Knoop1, Bjørn Egil Vikse, Einar Svarstad

  • 1Department of Clinical Medicine, Renal Research Group, University of Bergen, Bergen, Norway; Department of Medicine, Haukeland University Hospital, Bergen, Norway.

American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|June 26, 2013
PubMed
Summary

Patients with Immunoglobulin A nephropathy (IgAN) face double the expected mortality rate, particularly after starting renal replacement therapy (RRT). However, the risk of end-stage renal disease is higher than the risk of death.

Keywords:
Immunoglobulin A nephropathyend-stage renal diseasemortalityprognosisrisk factor

More Related Videos

Dioscin Mediated IgA Nephropathy Alleviation by Inhibiting B Cell Activation In Vivo and Decreasing Galactose-Deficient IgA1 Production In Vitro
14:18

Dioscin Mediated IgA Nephropathy Alleviation by Inhibiting B Cell Activation In Vivo and Decreasing Galactose-Deficient IgA1 Production In Vitro

Published on: October 13, 2023

Related Experiment Videos

Last Updated: May 10, 2026

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice
05:39

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice

Published on: July 8, 2020

Dioscin Mediated IgA Nephropathy Alleviation by Inhibiting B Cell Activation In Vivo and Decreasing Galactose-Deficient IgA1 Production In Vitro
14:18

Dioscin Mediated IgA Nephropathy Alleviation by Inhibiting B Cell Activation In Vivo and Decreasing Galactose-Deficient IgA1 Production In Vitro

Published on: October 13, 2023

Area of Science:

  • Nephrology
  • Epidemiology
  • Public Health

Background:

  • Immunoglobulin A nephropathy (IgAN) is the most prevalent form of glomerulonephritis worldwide.
  • Limited research exists on mortality rates in IgAN patients compared to the general population.

Purpose of the Study:

  • To investigate and quantify mortality risks in patients diagnosed with IgAN.
  • To compare the mortality of IgAN patients with the age- and sex-adjusted general population.

Main Methods:

  • A cohort study utilizing record linkage between Norwegian kidney biopsy, cause of death, and renal registries.
  • Inclusion of 633 patients diagnosed with IgAN between 1988 and 2004.
  • Analysis of predictors including estimated glomerular filtration rate (eGFR), age, and sex.

Main Results:

  • The standardized mortality ratio (SMR) for IgAN patients was 1.9, indicating twice the expected mortality.
  • Mortality risk increased significantly with declining eGFR, with SMRs of 1.0, 1.9, and 3.6 for eGFR ≥60, 30-60, and <30 mL/min/1.73 m(2) respectively.
  • Mortality risk was not significantly elevated before renal replacement therapy (RRT) (SMR 1.3) but increased substantially after RRT initiation (SMR 4.9). Cardiovascular disease was the leading cause of death (45%).

Conclusions:

  • IgAN patients experience a doubled overall mortality rate compared to the general population.
  • The increased mortality risk is primarily observed after the initiation of renal replacement therapy (RRT).
  • The risk of developing end-stage renal disease is notably higher than the risk of death for IgAN patients.